GlassScriptPhysician profile
Nicholas James Garn
NPI 1063433662
$10,705.38
in general payments reported to CMS, 2019-2025
25 companies · $4,814 in 2025
The $4,814 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $515 · 2021: $933 · 2022: $1,189 · 2023: $981 · 2024: $1,107 · 2025: $4,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,677 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,068 · Entertainment: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,676.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,068.04 |
| Entertainment | $157.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,241.37 | 2019-2025 | Dailies Total1, Precision 1, Air Optix Color |
| Carl Zeiss Meditec USA, INC. | $1,268.80 | 2025 | |
| Bausch & Lomb Americas INC. | $1,222.62 | 2022-2025 | Infuse, Biotrue One Day, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $926.89 | 2019-2021 | |
| Coopervision INC. | $658.00 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $595.41 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $427.48 | 2024-2025 | Xdemvy |
| Allergan, INC. | $351.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $329.21 | 2020-2023 | |
| Kala Pharmaceuticals, INC. | $303.94 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $209.85 | 2024-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $204.42 | 2019-2025 | Cequa |
| Optos, INC. | $200.90 | 2020-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $195.73 | 2022-2025 | |
| Oyster Point Pharma, INC. | $151.90 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $97.46 | 2024 | Oxervate |
| Harrow Eye, LLC | $77.97 | 2025 | Vevye |
| Horizon Therapeutics Plc | $43.17 | 2020-2023 | Tepezza |
| Lombart Brothers, INC. | $43.07 | 2019 | |
| Aerie Pharmaceuticals, INC. | $38.20 | 2021 | |
| Abb Con-Cise Optical Group LLC | $28.82 | 2024 | Spectacle Lenses, Contact Lens |
| Quidel Corporation | $28.21 | 2019 | |
| Biotissue Holdings INC. | $23.72 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $19.28 | 2021 | |
| Maculogix, INC. | $17.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Garn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.